AMENDMENT #1 TO AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • August 9th, 2006 • Avanir Pharmaceuticals • Pharmaceutical preparations
This Amendment #1 effective as of the last date on the signature page hereof (“Effective Date”), by and between CIMA LABS INC. (“CIMA”) and Alamo Pharmaceuticals, LLC (“ALAMO”) and amends and supplements that certain Amended And Restated Development, License and Supply Agreement between CIMA and ALAMO dated August 22, 2005 (the “Agreement”).
UNIT PURCHASE AGREEMENT by and among Avanir Pharmaceuticals (the “Buyer”), The Parties Listed on Schedule A Attached Hereto (the “Sellers”) and Alamo Pharmaceuticals, LLC (the “Company”) with respect to all outstanding units representing membership...Unit Purchase Agreement • August 9th, 2006 • Avanir Pharmaceuticals • Pharmaceutical preparations • California
This UNIT PURCHASE AGREEMENT dated as of May 22, 2006 (this “Agreement”), is entered into by and among Avanir Pharmaceuticals, a California corporation (the “Buyer”), the parties listed on Schedule A attached hereto (the “Sellers”) and Alamo Pharmaceuticals, LLC, a California limited liability company (the “Company”).
AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT by and between CIMA LABS INC. and ALAMO PHARMACEUTICALS, LLC dated as of August 22, 2005Development, License and Supply Agreement • August 9th, 2006 • Avanir Pharmaceuticals • Pharmaceutical preparations • New York
This AMENDED AND RESTATED DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this “Agreement”), dated and effective as of August 22, 2005 (the “Effective Date”), is by and between CIMA LABS INC., a Delaware corporation (“CIMA”), and ALAMO PHARMACEUTICALS, LLC, a California Limited Liability Company (“Alamo”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 9th, 2006 • Avanir Pharmaceuticals • Pharmaceutical preparations • California
This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 24, 2006, by and among Avanir Pharmaceuticals, a California corporation (the “Company”) and Neal R. Cutler (“Cutler”).
